Ascentage Research Development from 2010 to 2026
| AAPG Stock | 23.82 0.62 2.67% |
Research Development | First Reported 2016-06-30 | Previous Quarter 503.2 M | Current Value 528.6 M | Quarterly Volatility 168.2 M |
Check Ascentage Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ascentage Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 112.5 M, Interest Expense of 41.4 M or Selling General Administrative of 117.8 M, as well as many indicators such as Price To Sales Ratio of 42.69, Dividend Yield of 0.0 or PTB Ratio of 137. Ascentage financial statements analysis is a perfect complement when working with Ascentage Pharma Valuation or Volatility modules.
Ascentage | Research Development | Build AI portfolio with Ascentage Stock |
The Research Development trend for Ascentage Pharma Group offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Ascentage Pharma is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Ascentage Pharma's Research Development Growth Pattern
Below is the plot of the Research Development of Ascentage Pharma Group over the last few years. It is Ascentage Pharma's Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ascentage Pharma's overall financial position and show how it may be relating to other accounts over time.
| Research Development | 10 Years Trend |
|
Research Development |
| Timeline |
Ascentage Research Development Regression Statistics
| Arithmetic Mean | 408,163,840 | |
| Geometric Mean | 270,445,895 | |
| Coefficient Of Variation | 84.43 | |
| Mean Deviation | 304,264,772 | |
| Median | 249,565,000 | |
| Standard Deviation | 344,626,829 | |
| Sample Variance | 118767.7T | |
| Range | 986.6M | |
| R-Value | 0.88 | |
| Mean Square Error | 28162.7T | |
| R-Squared | 0.78 | |
| Slope | 60,184,411 | |
| Total Sum of Squares | 1900282.4T |
Ascentage Research Development History
About Ascentage Pharma Financial Statements
Ascentage Pharma stakeholders use historical fundamental indicators, such as Ascentage Pharma's Research Development, to determine how well the company is positioned to perform in the future. Although Ascentage Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ascentage Pharma's assets and liabilities are reflected in the revenues and expenses on Ascentage Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ascentage Pharma Group. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Research Development | 1.1 B | 570 M |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of Ascentage Pharma Correlation against competitors. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Can Biotechnology industry sustain growth momentum? Does Ascentage have expansion opportunities? Factors like these will boost the valuation of Ascentage Pharma. If investors know Ascentage will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Ascentage Pharma demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (2.10) | Revenue Per Share | Quarterly Revenue Growth (0.72) | Return On Assets | Return On Equity |
The market value of Ascentage Pharma is measured differently than its book value, which is the value of Ascentage that is recorded on the company's balance sheet. Investors also form their own opinion of Ascentage Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascentage Pharma's true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because Ascentage Pharma's market value can be influenced by many factors that don't directly affect Ascentage Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Ascentage Pharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Ascentage Pharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Ascentage Pharma's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.